Sphingosine-1-Phosphate Receptor 1 (S1PR1) Peptid
S1PR1
WB, Inhibition
-
- Target Alle S1PR1 Produkte
- S1PR1 (Sphingosine-1-Phosphate Receptor 1 (S1PR1))
- Applikation
- Western Blotting (WB), Blocking Antibody (Inhibition)
-
-
- Applikationshinweise
- Blocking: Incubate undiluted antibody (ABIN187786) with at least a 50 fold stoichiometric excess of blocking peptide at 37°C for 20 minutes (molecular weights of peptide and antibody are ~2.5 kDa and ~160 kDa, respectively.) Antibody can then be diluted to a concentration suitable for Western blotting. Example: 10 µl or 10 µg of anti-EDG-1 (PC-085) are added to 10 µg of blocking peptide for a total volume of 20 µl. The mixture is allowed to incubate for 20 minutes at 37°C prior to dilution in suitable buffer (for Western blot, etc.)
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Solution at 1 mg/ml in PBS.
- Lagerung
- -20 °C
-
- Target
- S1PR1 (Sphingosine-1-Phosphate Receptor 1 (S1PR1))
- Hintergrund
- EDG-1 belongs to a family of G-protein coupled receptors whose ligands are lysophospholipids. The ligand for EDG-1 is sphingosine-1- phosphate. There are 8 known members of the EDG receptor family and they are implicated in mediating growth related effects such as induction of cellular proliferation, alterations in differentiation and survival and suppression of apoptosis. They also evoke cellular effector functions that are dependent on cytoskeletal responses such as contraction, secretion, adhesion and chemotaxis. EDG receptors are developmentally regulated and differ in tissue distribution. The couple to multiple types of G proteins to signal through ras and MAP kinase, rho, phospholipase C and several protein tyrosine kinases. EDG-1 is expressed in cardiovascular, leukocyte containing and other tissues. Use: Blocking peptide for use in Western blotting with Anti-EDG-1 polyclonal antibody.
-
Sie sind hier:
